Business
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
UCB, a global biopharmaceutical company, today announced that Neurology has published results from a multicenter retrospective chart review study of investigational pyrimidine nucleoside and/or nucleotide therapy in people living with thymidine kinase 2 deficiency (TK2d). The results indicated that pyrimidine nucleoside and/or nucleotide therapy may reduce risk of death and can impact functional outcomes in patients with TK2d.1
About this update from United Community Banks, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"First published data from a multicenter retrospective chart review study to explore the safety and efficacy of pyrimidine nucleoside and/or nucleotide therapy in patients with thymidine kinase 2 deficiency (TK2d).1","length":214,"tagName":"p"}]},{"val":[{"type":"text","content":"Neurology published results from a multicenter retrospective chart review study of pyrimidine nucleoside and/or nucleotide therapy which showed a reduction in the risk of death by 95%.1","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"UCB's pyrimidine nucleoside therapy is currently under regulatory review by US and EU regulatory authorities. If approved, it will become the first treatment for TK2d in patients with an age of symptom onset on or before 12 years.2","length":235,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":634,"olType":false},{"type":"text","content":"ATLANTA, Oct. 13, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Neurology has published results from a multicenter retrospective chart review study of investigational pyrimidine nucleoside and/or nucleotide therapy in people living with thymidine kinase 2 deficiency (TK2d). The results indicated that pyrimidine nucleoside and/or nucleotide therapy may reduce risk of death and can impact functional outcomes in patients with TK2d.1","length":470,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/UCB, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/UCB, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/b8934a241b3f4be76014bb4ac3438a0c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xSTzopCi9exEzsCW8PHvIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b8934a241b3f4be76014bb4ac3438a0c","width":400,"height":95}},"href":"https://mma.prnewswire.com/media/677397/With_Tag_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"TK2d is an ultra-rare, life-threatening, genetic mitochondrial disease characterized by progressive and severe muscle weakness (myopathy), which can impact the ability to walk, eat, and breathe independently.3,4,5,6,7","length":217,"tagName":"p"},{"type":"text","content":"Key findings of the Neurology ...